217 related articles for article (PubMed ID: 33677615)
1. Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma.
Shabsigh A; Kleinmann N; Smith AB; Scherr D; Seltzer E; Schoenberg M; Lerner SP
Cancer Chemother Pharmacol; 2021 Jun; 87(6):799-805. PubMed ID: 33677615
[TBL] [Abstract][Full Text] [Related]
2. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Kleinmann N; Matin SF; Pierorazio PM; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky S; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Stern J; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Adibi M; Amin MB; Seltzer E; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Schoenberg M; Lerner SP
Lancet Oncol; 2020 Jun; 21(6):776-785. PubMed ID: 32631491
[TBL] [Abstract][Full Text] [Related]
3. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
Matin SF; Pierorazio PM; Kleinmann N; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky SG; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Seltzer E; Schoenberg M; Lerner SP
J Urol; 2022 Apr; 207(4):779-788. PubMed ID: 34915741
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas.
Porta C; Giannatempo P; Rizzo M; Lucarelli G; Ditonno P; Battaglia M
Expert Opin Pharmacother; 2020 Dec; 21(18):2199-2204. PubMed ID: 32870051
[TBL] [Abstract][Full Text] [Related]
5. Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
Rose KM; Murray KS; Labbate C; Woldu S; Linehan J; Jacob J; Kaimakliotis H; Dickstein R; Feldman A; Matin SF; Lotan Y; Humphreys MR; Sexton WJ
Eur Urol Focus; 2023 Sep; 9(5):807-812. PubMed ID: 37059620
[TBL] [Abstract][Full Text] [Related]
6. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.
Linehan J; Gottlieb J; Woldu SL; Labbate C; Rose K; Sexton W; Kaimakliotis H; Jacob J; Dickstein R; Nieder A; Bjurlin M; Humphreys M; Ghodoussipor S; Quek M; O'Donnell M; Eisner BH; Feldman AS; Matin SF; Lotan Y; Murray KS
Eur Urol Focus; 2023 Nov; 9(6):1052-1058. PubMed ID: 37263827
[TBL] [Abstract][Full Text] [Related]
7. Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Woldu SL; Labbate C; Murray KS; Rose K; Sexton W; Tachibana I; Kaimakliotis H; Jacob J; Dickstein R; Linehan J; Nieder A; Bjurlin MA; Humphreys M; Ghodoussipour S; Quek ML; O'Donnell M; Eisner BH; Feldman AS; Matin SF; Lotan Y
Urol Oncol; 2023 Mar; 41(3):147.e15-147.e21. PubMed ID: 36424224
[TBL] [Abstract][Full Text] [Related]
8. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
Kaimakliotis HZ; Tachibana I; Woldu S; Labbate C; Jacob J; Murray K; Rose K; Sexton W; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner BH; Matin SF; Lotan Y; Feldman AS
Urol Oncol; 2023 Sep; 41(9):387.e1-387.e7. PubMed ID: 37246135
[TBL] [Abstract][Full Text] [Related]
9. Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
Rosen GH; Nallani A; Muzzey C; Murray KS
J Urol; 2022 Jun; 207(6):1302-1311. PubMed ID: 35130080
[TBL] [Abstract][Full Text] [Related]
10. Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
Chevli KK; Shore ND; Trainer A; Smith AB; Saltzstein D; Ehrlich Y; Raman JD; Friedman B; D'Anna R; Morris D; Hu B; Tyson M; Sankin A; Kates M; Linehan J; Scherr D; Kester S; Verni M; Chamie K; Karsh L; Cinman A; Meads A; Lahiri S; Malinowski M; Gabai N; Raju S; Schoenberg M; Seltzer E; Huang WC
J Urol; 2022 Jan; 207(1):61-69. PubMed ID: 34433303
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Labbate C; Woldu S; Murray K; Rose K; Sexton W; Tachibana I; Kaimakliotis H; Jacob J; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner B; Feldman A; Lotan Y; Matin SF
J Urol; 2023 May; 209(5):872-881. PubMed ID: 36657029
[TBL] [Abstract][Full Text] [Related]
13. Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report".
Song Y; Du Y; Qin C; Xu T
World J Urol; 2022 May; 40(5):1251-1252. PubMed ID: 35191990
[No Abstract] [Full Text] [Related]
14. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review.
Cutress ML; Stewart GD; Zakikhani P; Phipps S; Thomas BG; Tolley DA
BJU Int; 2012 Sep; 110(5):614-28. PubMed ID: 22471401
[TBL] [Abstract][Full Text] [Related]
15. UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma.
Kokorovic A; Matin SF
Ther Adv Med Oncol; 2020; 12():1758835920937950. PubMed ID: 32670424
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
Prasad SM; Huang WC; Shore ND; Hu B; Bjurlin M; Brown G; Genov P; Shishkov D; Khuskivadze A; Ganev T; Marchev D; Orlov I; Kopyltsov E; Zubarev V; Nosov A; Komlev D; Burger B; Raju S; Meads A; Schoenberg M
J Urol; 2023 Oct; 210(4):619-629. PubMed ID: 37548555
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of Different Prophylactic Intravesical Chemotherapy Regimens for Bladder Cancer Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinomas: A Retrospective 2-center Study.
Huang Y; Cen J; Liu Z; Wei J; Chen Z; Feng Z; Lu J; Fang Y; Zhou F; Luo J; Mo C; Chen W
Technol Cancer Res Treat; 2019 Jan; 18():1533033819844483. PubMed ID: 30987527
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Centre Prospective Non-Randomized Trial.
Gallioli A; Boissier R; Territo A; Vila Reyes H; Sanguedolce F; Gaya JM; Regis F; Subiela JD; Palou J; Breda A
J Endourol; 2020 May; 34(5):573-580. PubMed ID: 32164441
[No Abstract] [Full Text] [Related]
19. Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomy.
Gulamhusein A; Silva P; Cullen D; Tran M; Mumtaz F; Patki P; Barod R; Bex A
BJU Int; 2020 Dec; 126(6):739-744. PubMed ID: 32638490
[TBL] [Abstract][Full Text] [Related]
20. Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer.
Stover AM; Basak R; Mueller D; Lipman R; Teal R; Hilton A; Giannone K; Waheed M; Smith AB
J Urol; 2022 Sep; 208(3):580-588. PubMed ID: 35640276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
